Shu Cheng

1.1k total citations
35 papers, 702 citations indexed

About

Shu Cheng is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Shu Cheng has authored 35 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 9 papers in Pathology and Forensic Medicine and 7 papers in Oncology. Recurrent topics in Shu Cheng's work include Lymphoma Diagnosis and Treatment (8 papers), Genomics and Phylogenetic Studies (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Shu Cheng is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Genomics and Phylogenetic Studies (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Shu Cheng collaborates with scholars based in China, United States and France. Shu Cheng's co-authors include Meng Wu, Kang Wang, Wan Yee Lau, Masha Y. Niv, Jing Sun, Wei Guo, Jie Shi, Frédéric Y. Bois, Debashish Bhattacharya and Paul G. Falkowski and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Shu Cheng

33 papers receiving 694 citations

Peers

Countries citing papers authored by Shu Cheng

Since Specialization

Citations

This map shows the geographic impact of Shu Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu Cheng more than expected).

Fields of papers citing papers by Shu Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu Cheng. The network helps show where Shu Cheng may publish in the future.

Co-authorship network of co-authors of Shu Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Shu Cheng. A scholar is included among the top collaborators of Shu Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu Cheng. Shu Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06) 2025 ·Signal Transduction and Targeted Therapy ·(unknown), Qing Shi, Wei Tang, (unknown), Yiwen Cao, Mengmeng Ji, Zhong Zheng, Shu Cheng, Wang Li, Weili Zhao	2
2	Rehabilitation report of 2 cases of spinal cord ischemic injury after intra-aortic repair 2024 ·Medicine ·Shu Cheng, Xuan Li, (unknown), (unknown), Yi Rao, Yang Zhang, Jinlun Wu, (unknown), E‐Liisa Laakso	1
3	Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma 2024 ·Signal Transduction and Targeted Therapy ·Jie Xiong, Shu Cheng, Xiao Gao, Shanhe Yu, Yuting Dai, Xin‐Yun Huang, Huijuan Zhong, Chao‐Fu Wang, Hongmei Yi, Hao Zhang, Weiguo Cao, (unknown), Wei Tang, Yan Zhao, Pengpeng Xu, Li Wang, Weili Zhao	4
4	KMT2D mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC/TGF-β1 axis 2024 ·International Journal of Biological Sciences ·(unknown), Yue Zhu, Hongmei Yi, (unknown), Li Wang, Shu Cheng, Pengpeng Xu, Haimin Xu, Luting Zhou, Yao‐Hui Huang, Chuanxin Huang, Di Fu, (unknown), Chao‐Fu Wang, (unknown)	3
5	A nuclear NKRF interacting long noncoding RNA controls EBV eradication and suppresses tumor progression in natural killer/T-cell lymphoma 2023 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Wenfang Wang, Huijuan Zhong, Shu Cheng, Di Fu, Yan Zhao, (unknown), Jie Xiong, Weili Zhao	5
6	Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma With Multiple Abnormal Immunologic Markers 2022 ·Frontiers in Oncology ·Lingshuang Sheng, Di Fu, Yiwen Cao, Yujia Huo, Shuo Wang, Rong Shen, Pengpeng Xu, Shu Cheng, Li Wang, Weili Zhao	6
7	The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Pengpeng Xu, Rong Shen, (unknown), Shu Cheng, Li Wang, Yang Liu, Lu Zhang, Ruiqi Huang, Xiaopeng Ma, (unknown), (unknown), Yiling Yu, Weili Zhao	6
8	Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma 2022 ·Frontiers in Oncology ·Mengke Liu, Lili Cheng, Hongmei Yi, (unknown), Xiao Li, Di Fu, Yuting Dai, Hai Fang, Shu Cheng, Pengpeng Xu, Ying Qian, Feng Yan, Qian Liu, Li Wang, Weili Zhao	7
9	A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia 2021 ·Clinical Cancer Research ·Gang An, Daobin Zhou, Shu Cheng, Keshu Zhou, Jianyong Li, Jianfeng Zhou, Liping Xie, Jie Jin, Liye Zhong, Lingzhi Yan, Haiyi Guo, (unknown), Jinhua Zhong, Yiling Yu, (unknown), Lugui Qiu	25
10	De novo genome assembly of a foxtail millet cultivar Huagu11 uncovered the genetic difference to the cultivar Yugu1, and the genetic mechanism of imazethapyr tolerance 2021 ·BMC Plant Biology ·Jie Wang, (unknown), Lei Lan, (unknown), Shu Cheng, (unknown), Gang Huang, Guohua Du, Kang Yu, Xuemei Ni, Baolong Liu, Guoxiong Peng	13
11	Rapid Characterization of the Genetic Loci Controlling Commodity Traits of Chinese Hami Melon (Cucumis melo var. Saccharinensis Naud.) through Multiplexed Shotgun Genotyping 2019 ·Agronomy ·Shiming Li, Xuemei Ni, Qiuju Xia, Yunfei Li, Dong Xiao, (unknown), Zehua Li, Shu Cheng, Dong Cao, Zhenyu Zhang, Gengyun Zhang, Shancen Zhao, Baolong Liu, Yong Chen	3
12	Quantitative susceptibility mapping in combination with water-fat separation for simultaneous liver iron and fat fraction quantification 2018 ·European Radiology ·Huimin Lin, Hongjiang Wei, Naying He, Caixia Fu, Shu Cheng, Jun Shen, Baisong Wang, Xu Yan, Chunlei Liu, Fuhua Yan	29
13	Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus 2016 ·Medicine ·Kang Wang, Wei Guo, (unknown), Yi Mao, Bei Sun, Jie Shi, Yaojun Zhang, Yan Meng, (unknown), (unknown), Meng Wu, Wan Yee Lau, Shu Cheng	89
14	Dual-Energy CT for Patients Suspected of Having Liver Iron Overload: Can Virtual Iron Content Imaging Accurately Quantify Liver Iron Content? 2015 ·Radiology ·Xian Luo, Xue Xie, Shu Cheng, Yi Yang, Jing Yan, Huan Zhang, (unknown), Bernhard Schmidt, (unknown)	52
15	Deciphering Primordial Cyanobacterial Genome Functions from Protein Network Analysis 2015 ·Current Biology ·Arye Harel, (unknown), Shu Cheng, Paul G. Falkowski, Debashish Bhattacharya	27
16	Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion 2015 ·Annals of Surgical Oncology ·Jing Sun, Kang Wang, (unknown), Wei Guo, Jie Shi, (unknown), Meng Wu, Wan Yee Lau, Shu Cheng	136
17	Serum LncRNAs Profiles Serve as Novel Potential Biomarkers for the Diagnosis of HBV-Positive Hepatocellular Carcinoma 2015 ·PLoS ONE ·Kang Wang, (unknown), Nan Li, Chun Gao, Jie Shi, (unknown), Feng Shen, (unknown), (unknown), Shu Cheng	57
18	Zonation related function and ubiquitination regulation in human hepatocellular carcinoma cells in dynamic vs. static culture conditions 2012 ·BMC Genomics ·Shu Cheng, Jean‐Matthieu Prot, Éric Leclerc, Frédéric Y. Bois	25
19	A Mechanistic Modeling Framework for Predicting Metabolic Interactions in Complex Mixtures 2011 ·Environmental Health Perspectives ·Shu Cheng, Frédéric Y. Bois	14
20	Molecular Dynamics Simulations and Elastic Network Analysis of Protein Kinase B (Akt/PKB) Inactivation 2010 ·Journal of Chemical Information and Modeling ·Shu Cheng, Masha Y. Niv	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact